Product Description
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Jiangsu Hengrui Medicine Co
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, China
Active Clinical Trial Count: 3
Highest Development Phases
Phase 2: Prostate Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
HRS-5041-201 | P2 |
Recruiting |
Prostate Cancer |
2025-09-01 |
|
HRS-5041-101 | P1 |
Recruiting |
Prostate Cancer |
2025-08-31 |
39% |
HRS-5041-102 | P1 |
Recruiting |
Prostate Cancer |
2024-12-03 |